Patents Assigned to Aventis Pasteur Limited
-
Patent number: 6503514Abstract: Attenuated strains of Mycobacterium, particularly species of the tuberculosis complex, have the mycobacterial cell entry (mce) gene functionally disabled. The gene may be disabled by an insertion into the gene which disrupts the mycobacterial cell entry function thereof of a selectable marker which is used for screen for homologous recombinants in which a double cross-over event has been effected. The attenuated strains may be used in the immunization of hosts against Mycobacterium disease.Type: GrantFiled: July 7, 2000Date of Patent: January 7, 2003Assignee: Aventis Pasteur LimitedInventors: Bruno Flesselles, Michel H. Klein
-
Patent number: 6486135Abstract: Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may lack a sequence encoding the homologous signal peptide but possessing a heterologous signal peptide enhancing RSV F protein expression. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: May 12, 2000Date of Patent: November 26, 2002Assignee: Aventis Pasteur LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Patent number: 6482928Abstract: The crystal structure of the Fab′ fragment of Mab 2F5, a potent neutralizer of both laboratory strains and primary clinical isolates of most clades of HIV-1, both uncompleted and completed with the largely conserved peptide sequence ELDKWAS of the viral envelope protein gp41, has been elucidated and the characteristics of peptide-protein interactions determined. Having regard to such determination, the peptide-mimetics are constrained in the three-dimensional structure to provide an increased immunogenicity to the epitope sequence.Type: GrantFiled: April 13, 1999Date of Patent: November 19, 2002Assignee: Aventis Pasteur Limited and University of TorontoInventors: Emil F. Pai, Michel H. Klein, Pele Chong, Arthur Pedyczak
-
Patent number: 6475780Abstract: A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo.Type: GrantFiled: October 20, 2000Date of Patent: November 5, 2002Assignee: Aventis Pasteur LimitedInventors: Mark Parrington, Xiaomao Li, Michel H. Klein
-
Patent number: 6471996Abstract: Copolymers designed for use as particulate carriers containing functionalizable amino acid subunits for coupling with targeting ligand are described. The copolymers are polyesters composed of &agr;-hydroxy acid subunits such as D,L-lactide and &agr;-amino acid subunits such as serine or in the preferred embodiment, terpolymers of D,L-lactide and glycolide and &agr;-amino acid subunits such as serine. Stable vaccine preparations useful as delayed release formulations containing antigen(s) or antigen(s) and co-adjuvants encapsulated within or physically mixed with polymeric microparticles are described. The particulate carriers are useful for delivering agents to the immune system of a subject by mucosal or parenteral routes to produce immune responses, including antibody responses.Type: GrantFiled: February 11, 2000Date of Patent: October 29, 2002Assignee: Aventis Pasteur LimitedInventors: Kenneth K. Sokoll, Pele Chong, Michel H. Klein
-
Patent number: 6464979Abstract: Immunogenic compositions including vaccines are described that comprise an outer membrane antigen extract of a strain of Chlamydia and are effective in protection against disease caused by Chlamydia infection. The immunogenic compositions may comprise the major outer membrane protein (MOMP) of Chlamydia which may be in a homooligomeric form or complexed with at least one other antigen of Chlamydia. The immunogenic composition may include an immunostimulating complex (ISCOM) and the outer membrane antigen may be incorporated therein. The immunogenic compositions have utility as chlamydial vaccines and in diagnostic applications.Type: GrantFiled: September 12, 1996Date of Patent: October 15, 2002Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Brian J. Underdown
-
Patent number: 6455050Abstract: Immunogenic envelope glycoproteins are produced from enveloped virus, such as of the paramyxoviridae family, particularly PIV-3 and RSV, by culturing the virus in the substantial absence of exogenous serum proteins, isolating the virus from the tissue culture, solubilizing the envelope glycoproteins and isolating the solubilized envelope glycoproteins by chromatography.Type: GrantFiled: April 26, 1995Date of Patent: September 24, 2002Assignee: Aventis Pasteur LimitedInventors: Mary Elizabeth Ewasyshyn, Barry Ian Caplan, Anne-Marie Bonneau, Michel Henri Klein
-
Patent number: 6451322Abstract: Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product, eliminate integrase activity of the pol gene, product and eliminate RNase H activity of the pol gene product through genetic manipulation of the gag and pol genes. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis.Type: GrantFiled: February 26, 1999Date of Patent: September 17, 2002Assignee: Aventis Pasteur LimitedInventors: Benjamin Rovinski, Shi-Xian Cao, Fei-Long Yao, Roy Persson, Michel H. Klein
-
Patent number: 6448386Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.Type: GrantFiled: March 19, 1998Date of Patent: September 10, 2002Assignee: Aventis Pasteur LimitedInventors: Ken Sasaki, Robin E. Harkness, Sheena M. Loosmore, Pele Chong, Michel H. Klein
-
Patent number: 6444444Abstract: A gene from a strain of Mycobacterium encoding a protein of molecular weight between about 45 to about 60 kDa and associated with cell binding and cell entry was cloned. The genes and encoded protein have utility in immunogenic preparations or diagnostic applications.Type: GrantFiled: July 10, 1996Date of Patent: September 3, 2002Assignee: Aventis Pasteur LimitedInventors: Naveen N. Anand, Michel H. Klein
-
Patent number: 6440701Abstract: Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.Type: GrantFiled: April 14, 1998Date of Patent: August 27, 2002Assignee: Aventis Pasteur LimitedInventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
-
Patent number: 6440425Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.Type: GrantFiled: March 26, 1996Date of Patent: August 27, 2002Assignee: Aventis Pasteur LimitedInventors: Ken Sasaki, Robin E. Harkness, Sheena M. Loosmore, Pele Chong, Michel H. Klein
-
Patent number: 6440424Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, has a molecular mass of about 200 kDa. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.Type: GrantFiled: June 7, 1995Date of Patent: August 27, 2002Assignee: Aventis Pasteur LimitedInventors: Ken Sasaki, Robin E. Harkness, Sheena M. Loosmore, Michel H. Klein
-
Patent number: 6437096Abstract: Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.Type: GrantFiled: January 3, 1997Date of Patent: August 20, 2002Assignee: Aventis Pasteur LimitedInventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
-
Patent number: 6432669Abstract: Protective high molecular weight (HMW) proteins are produced recombinantly by expression from E. coli by using a promoter effective in E. coli and a nucleic acid molecule which contains a modified operon of a non-typeable strain of Haemophilus. The modified operon contains the portion only of the A region which encodes the mature HMW protein and the complete B and C regions of the operon. Enhanced levels of expression of the HMW proteins can be achieved by including the E. coli cer gene, a further copy of the portion of the A region of the operon encoding the mature protein or both in the expression vector. Nucleotide and deduced amino acid sequences of the hmw1 and hmw2 genes and HMW1 and HMW2 proteins, respectively of several non-typeable Haemophilus influenzae strain have been identified.Type: GrantFiled: December 8, 1998Date of Patent: August 13, 2002Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Michel H. Klein
-
Publication number: 20020081682Abstract: The present invention provides a method fo nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding an ATP/ADP translocase of a strain of Chlamydia pneumoniae and a promoter to effect expression of the ATP/ADP translocase gene in the host. Modifications are possible within the scope of this invention.Type: ApplicationFiled: June 28, 2001Publication date: June 27, 2002Applicant: Aventis Pasteur Limited.Inventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
-
Patent number: 6403081Abstract: Attenuated strains of Leishmania are provided in which at least one gene contributing to virulence of the strain and expressed in both the promastigote and amastigote forms of the strain is functionally disabled, such as, by deleting at least a portion of the gene or by mutagenesis of the gene. The attenuated strain may be used for administration to a host to confer protection against disease caused by a virulent Leishmania strain or as a diagnostic reagent.Type: GrantFiled: July 17, 2000Date of Patent: June 11, 2002Assignee: Aventis Pasteur LimitedInventors: Barbara Papadopoulou, Marc Ouellette, Martin Olivier
-
Patent number: 6399076Abstract: Acellular pertussis vaccines comprise purified toxin or toxoid thereof, filamentous haemagglutinin, pertactin and fimbrial agglutinogens formulated to confer protection to at least 70% of members of an at-risk population. The fimbrial agglutinogens may be prepared from a Bordetella strain, particularly a B. pertussis strain, by a multiple step procedure involving extraction of the fimbrial agglutinogens from cell paste and concentrating and purifying the extracted material.Type: GrantFiled: June 9, 1998Date of Patent: June 4, 2002Assignee: Aventis Pasteur LimitedInventors: John R. Vose, Raafat E. F. Fahim, Gail E. D. Jackson, Larry U. L. Tan, Andrew Herbert, Leslie Boux, Luis Barreto, John Thipphawong, Michel H. Klein
-
Patent number: 6395469Abstract: An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopotentiating, immunogenic and protective. The virus is grown on a vaccine quality cell line and harvested virus is purified under non-denaturing conditions to be substantially free from cellular and serum components. The purified RS virus is inactivated using &bgr;-propiolactone, a non-ionic detergent, particularly n-octyl-&agr;-D-glucopyranoside and n-octyl-&bgr;D-glucopyranoside, or ascorbic acid. The immunogenic composition may be formulated as a vaccine for in vivo administration to a human host. The immunogenic composition also may be used in diagnostic applications.Type: GrantFiled: June 7, 1995Date of Patent: May 28, 2002Assignee: Aventis Pasteur LimitedInventors: Sonia E. Sanhueza, Mary Elizabeth Ewasyshyn, Michel Henri Klein
-
Patent number: 6395714Abstract: A vector for eliciting an immune response to a host comprising a gene encoding the gp140 protein of the primary isolate of HIV-1, BX08, under the control of a promotor for expression of the protein in the host, specifically plasmid pCMV.gp140.BX08. Murine and human MHC class 1-restricted binding motifs contained in BX08 are identified.Type: GrantFiled: February 24, 1999Date of Patent: May 28, 2002Assignee: Aventis Pasteur LimitedInventors: Charles D. Y. Sia, Shi Xian Cao, Roy Persson, Benjamin Rovinski